**ECONOMIC IMPACT OF BIOLOGICAL TREATMENT OPTIMISATIONS IN RHEUMATOLOGICAL AND DERMATOLOGICAL DISEASES**

M.D. GIL-SIERRA¹, M.D.P. BRICEÑO CASADO², C. MORENO-RAMOS¹, M.A. BLANCO-CASTAÑO¹, C.M. CUADROS-MARTÍNEZ¹.

¹HOSPITAL UNIVERSITARIO DE PUERTO REAL, PHARMACY, PUERTO REAL, SPAIN.
²HOSPITAL UNIVERSITARIO DE JEREZ DE LA FRONTERA, HOSPITAL PHARMACY, JEREZ DE LA FRONTERA CÁDIZ, SPAIN.
³HOSPITAL UNIVERSITARIO JEREZ DE LA FRONTERA, PHARMACY, JEREZ DE LA FRONTERA, SPAIN.

**Section 4: Clinical Pharmacy Services**

**BACKGROUND**

Appropriate optimisation of biologic agents in immune-mediated inflammatory diseases can improve treatment efficiency by decreasing number of drug administrations.

**AIM**

To estimate economic impact of optimising the use of etanercept and adalimumab in patients with immune-mediated dermatological and rheumatological diseases.

**MATERIAL AND METHODS**

Descriptive retrospective study between November 2021 and September 2022

**RESULTS**

- **Patients**: 256 (182 of Internal Medicine department and 74 of Dermatology)
- **Total Patients**: 256 (182 of Internal Medicine department and 74 of Dermatology)
- **Distribution of drugs**: 171 patients received etanercept and 85 adalimumab.
- **Biochemical test and pharmaceutical interviews**: 258 (2 patients required 2 biochemical test and 2 pharmaceutical interviews).
- **Serum drug levels**: outside the optimal therapeutic ranges of drugs in 71.6% of cases.
- **Anti-drug antibodies**: 15 patients.
- **Treatment optimizations**: 115 patients [86 (74.8%) of Internal Medicine department and 29 (25.2%) of Dermatology].

**Economic impact**

Savings from biological therapy optimizations: difference between costs of real doses used with optimized regimens and hypothetical costs with doses used prior to treatment optimizations. The number of decreased drug administrations was estimated.

- **Total Patients**: 256 (182 of Internal Medicine department and 74 of Dermatology)
- **Distribution of drugs**: 171 patients received etanercept and 85 adalimumab.
- **Biochemical test and pharmaceutical interviews**: 258 (2 patients required 2 biochemical test and 2 pharmaceutical interviews).
- **Serum drug levels**: outside the optimal therapeutic ranges of drugs in 71.6% of cases.
- **Anti-drug antibodies**: 15 patients.
- **Treatment optimizations**: 115 patients [86 (74.8%) of Internal Medicine department and 29 (25.2%) of Dermatology].

**Total economic savings associated with optimization of biological therapies**: 68804.96 €
- **Internal Medicine department**: 53169,58€
- **Dermatology**: 15635.38€

**Average monthly savings for these treatment optimizations**: 6255 €/month

**Number of drug administrations avoided**: 777.

**CONCLUSION**

The optimization of etanercept and adalimumab regimens in our patients with immune-mediated dermatological and rheumatological diseases provided high efficiency by decreasing the number of drug administrations.

**CONTACT DATA**

E-mail: mangilsie@yahoo.com